Latest Conference Coverage


Cladribine Shows Efficacy, Tolerability Among Patients With MS Switching From Infusion DMTs

October 26th 2022

In a small real-world cohort, annualized relapse rates were reduced for patients with multiple sclerosis who switched to cladribine (Mavenclad; EMD Serono) from ocrelizumab (Ocrevus; Genentech), natalizumab (Tysabri; Biogen), and alemtuzumab (Lemtrada; Sanofi Genzyme).


Fingolimod Continues to Outperform Interferon in Long-Term PARADIGMS Study of Pediatric MS

October 26th 2022

The favorable annualized relapse rates for fingolimod over interferon beta-1a observed in the 2-year core phase continued in a 5-year open-label extension.


Ravulizumab Demonstrates Significant Ability to Reduce Relapses in NMOSD

October 26th 2022

Over a median of 73.5 weeks of follow-up time, zero adjudicated relapses were observed for those with AQP4+ NMOSD on ravulizumab.


Newest Updates in Multiple Sclerosis at ECTRIMS 2022: Tianrong Yeo, MBBS, MRCP, MMED, FAMS, MCI, PhD

October 26th 2022

The senior consultant for the department of neurology at the National Neuroscience Institute shares what he looks forward to at this year's ECTRIMS conference. [WATCH TIME: 2 minutes]


No Evidence of Elevated MS Relapse Risk Following Fertility Treatments

October 26th 2022

Among 43 cycles that achieved pregnancy, investigators observed decreases of annualized relapse rates from 0.26 to 0.09.


IFN 2022 Expands on Neurology Specialties and Positive Brain Health: Stephen Krieger, MD

October 25th 2022

The neurologist at the Corinne Goldsmith Dickinson Center for MS offered a brief overview of his experience at the 2022 IFN conference held in New York City on September 23-24. [WATCH TIME: 4 minutes]


NeurologyLive® Brain Games: October 23, 2022

October 23rd 2022

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the European Committee for Treatment and Research in Multiple Sclerosis.


Composite Speech Score Detects Longitudinal Cognitive Changes Better Than Some Traditional Measures

October 22nd 2022

The composite score, which consisted of 6 linguistic features and 3 acoustic features, was shown to be sensitive to measures of disease progression, with a potential to help understand treatment response.


Understanding the Utility of Specific Antibody Testing in Peripheral Neuropathies: Benjamin Claytor, MD

October 18th 2022

The assistant professor of neurology at Cleveland Clinic provided insight on the differences in ganglioside vs paranodal antibodies and their clinical use in various neuropathies. [WATCH TIME: 3 minutes]


Long-Term Goals of Guidelines for Painful Diabetic Neuropathy: Brian Callaghan, MD, MS

October 14th 2022

The associate professor at the University of Michigan described the ways recently published guidelines on diabetic neuropathies will change how conditions like Guillain-Barré syndrome and CIDP are managed. [WATCH TIME: 3 minutes]


Effects of Combination Therapies, Treatment Adverse Effects in Myasthenia Gravis: Nicholas Silvestri, MD, FAAN

October 13th 2022

The clinical professor at the University at Buffalo discussed the complexities of using combination therapies to treat myasthenia gravis, and whether adverse events play a major role in treatment decisions. [WATCH TIME: 3 minutes]


Advancing the Treatment Paradigm for Myasthenia Gravis and Looking Toward the Future

October 5th 2022

Nicholas Silvestri, MD, clinical professor at the University at Buffalo discussed topics related to the expansion of treatments for myasthenia gravis and the positive outlook of managing the disease.


Institutional Perspectives in Neurology, Chaired by Riley Bove, MD

October 5th 2022

Chaired by Riley Bove, MD, of the University of California, San Francisco (UCSF), the presentations also feature Emmanuelle Waubant, MD, PhD, of UCSF; William L. Conte, MD, MS, of Methodist Hospitals; and Maria K. Houtchens, MD, of Harvard Medical School. [WATCH TIME: 1 hour, 31 minutes]


Virtual Yoga Program Beneficial for Individuals With Functional Neurological Disorder

October 4th 2022

Danielle Kipnis, MA, of Columbia University, discussed the practice of yoga for people with functional neurological disorders from her research and recommendations for future studies in the field.


Progression of New Treatments for Duchenne Muscular Dystrophy: Emma Ciafaloni, MD

October 3rd 2022

The professor of Neurology and Pediatrics at University of Rochester Medical Center discusses the progression of new treatment for Duchenne muscular dystrophy and provides suggestions for moving forward with research in the field. [WATCH TIME: 5 minutes]


Recommendations for Clinical Trial Design in Duchenne Muscular Dystrophy: Emma Ciafaloni, MD

October 2nd 2022

The professor of neurology and pediatrics at University of Rochester Medical Center gives some recommendations for the improvement in clinical trial design for patients with rare diseases such as Duchenne muscular dystrophy. [WATCH TIME: 5 minutes]


CNM-Au8 Slows Disease Progression in ALS in RESCUE-ALS Phase 2 Trial

October 1st 2022

RESCUE-ALS trial, a phase 2 randomized controlled study, showed that ALS disease progression was significantly reduced with CNM-Au8 Treatment.


Understanding Safety, Amyloid-Related Imaging Abnormalities With Lecanemab: Sharon Cohen, MD, FRCPC

September 30th 2022

The neurologist and assistant professor at the University of Toronto discussed the real, but tepid significance of amyloid-related imaging abnormalities seen from lecanemab in early-stage Alzheimer disease. [WATCH TIME: 3 minutes]


Sleep Breathing Disorders Appear Common for Patients with Duchenne Muscular Dystrophy

September 30th 2022

A questionnaire-based study from Saudi Arabia on sleep quality revealed that sleep-related disorders, such as obstructive sleep apnea, are relatively common in patients with Duchenne muscular dystrophy.


Diagnosis of Myotonic Dystrophy Demonstrates an Association With Depression

September 29th 2022

Findings from a cross-sectional survey revealed a significant association between depression and a diagnosis of myotonic dystrophy, and that symptoms impacting quality of life are more common in neuromuscular disorders.


Tollgate-Related Prognostic Factors Have Stronger Effect on ALS Progression Timing Through Disease Tollgates

September 28th 2022

A study on ALS progression suggested that tollgate-related prognostic factors have a stronger effect on the time trajectories of passing ALS tollgates in comparison with standard prognostic factors.


NeuroVoices: Emma Ciafaloni, MD, on the Vast Expansion of Innovative Approaches to Duchenne Muscular Dystrophy

September 28th 2022

The professor of neurology and pediatrics at the University of Rochester Medical Center provided insight on the emerging therapies and advancements for treating patients with Duchenne muscular dystrophy.


New Treatments for Duchenne Muscular Dystrophy: Emma Ciafaloni, MD

September 27th 2022

New Treatments for Duchenne Muscular Dystrophy: Emma Ciafaloni, MD The professor of Neurology and Pediatrics at University of Rochester Medical Center discusses the new and future treatments for Duchenne muscular dystrophy. [WATCH TIME: 4 minutes]


Virtual Reality Training May Improve Quality of Care in Lower Limb Spasticity With OnabotulinumtoxinA

September 27th 2022

Results from pilot program using a VR-based platform suggest medical trainees may benefit from further VR training to gain a complete baseline knowledge of treating lower limb spasticity with onabotulinumtoxinA.


Tele-Yoga Breathing for Respiratory Function Proves Feasibility in Amyotrophic Lateral Sclerosis

September 26th 2022

A nonrandomized pilot study demonstrated high adherence rates and acceptability ratings with tele-yoga breathing in patients with ALS, proving that it is a safe and feasible practice.


Vaccinated Individuals With Myasthenia Gravis With COVID-19 Infection are More at Health Risk

September 26th 2022

Adults with myasthenia gravis who contracted COVID-19 were at twice the risk of hospitalization, ICU admission, and death based on data from a recent population-based study.


Evaluating the Treatment Evolution of Myasthenia Gravis and Use of Immunosuppressants: Nicholas Silvestri, MD, FAAN

September 26th 2022

The clinical professor of neurology at the University at Buffalo provided insight on the advances in treatment options for patients with myasthenia gravis over the past few decades. [WATCH TIME: 3 minutes]

© 2023 MJH Life Sciences

All rights reserved.